TokenPost·
Nektar Therapeutics Reports Q3 Net Loss of $55.7 Million
Revenue declined year over year, while cash and investments in marketable securities totaled $952.9 million at quarter-end.
More news
- Crypto BriefingNvidia evaluates CEO succession, considers internal and external candidates
- TokenPostPRF Technologies Ltd. Requests Hearing After Nasdaq Delisting Determination
- TokenPostFounders 100 ETF CIO Urges Nvidia to Bring Back Jensen Huang
- TokenPostNu Holdings Beats Q3 Revenue Estimates as It Begins Expanding Beyond Latin America
- Crypto BriefingGrayscale says crypto sectors are drifting away from Bitcoin’s orbit
- TokenPostURNM ETF and Binance’s Perpetual Contract Track Different Markets